RxDoctor Payments DataLook up a doctor →

Edythe Boitnott, NP

Family · Danville, VANPI 1780718973

Payments from drug & device makers

$10,944in general payments, 2019–2025

Across 676 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$915
  • Lundbeck LLC$608
  • UCB, Inc.$583
  • Argenx US, Inc.$461
  • Lilly USA, LLC$424
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$10,914100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,944 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$20,771
Medicare patients
125
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab12$101,196
CopaxoneGlatiramer Acetate13$75,816
Aimovig AutoinjectorErenumab-Aooe87$74,243
AptiomEslicarbazepine Acetate29$37,598
Nurtec OdtRimegepant Sulfate17$36,842
XcopriCenobamate24$29,781
UbrelvyUbrogepant21$25,741
RytaryCarbidopa/Levodopa23$21,797
FycompaPerampanel15$15,614
Emgality PenGalcanezumab-Gnlm15$11,193
Oxtellar XrOxcarbazepine12$8,318
DilantinPhenytoin Sodium Extended25$6,839
Sumatriptan18$6,437
Gabapentin251$4,292
Memantine Hcl106$2,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$410$75,81613 claims
PfizerNurtec Odt, Dilantin$187$43,68042 claims
Sunovion Pharmaceuticals Inc.Aptiom$305$37,59829 claims
SK Life Science, Inc.Xcopri$322$29,78124 claims
AbbVieUbrelvy$2,303$25,74121 claims
Amneal Pharmaceuticals LLCRytary$200$21,79723 claims
Eisai Inc.Fycompa$137$15,61415 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$124$8,31812 claims
Upsher-smith Laboratories LLCTopiramate$131$2,238144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Danville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →